These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 15988137)

  • 1. Atorvastatin Downregulates
    Araujo-Lima CF; Christoni LSA; Justo G; Soeiro MNC; Aiub CAF; Felzenszwalb I
    Oxid Med Cell Longev; 2018; 2018():7820890. PubMed ID: 29849914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
    Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
    Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
    Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
    Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
    Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M
    J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.
    Vandjelovic N; Zhu H; Misra HP; Zimmerman RP; Jia Z; Li Y
    Mol Cell Biochem; 2012 May; 364(1-2):71-7. PubMed ID: 22207075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of micronuclei in CHO cells by bleomycin but not by X-irradiation is decreased by treatment with HMG-CoA reductase inhibitors.
    Iwashita J; Kodama S; Nakashima M; Sasaki H; Taniyama K; Watanabe M
    J Radiat Res; 2005 Jun; 46(2):191-5. PubMed ID: 15988137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.